Eleven Biotherapeutics said it is initiating a late-stage study to assess the efficacy, safety and tolerability of its experimental drug EBI-005 in patients with dry eye disease. The firm said data from the trial, which will involve around 650 patients, should be available by early next year.

Related Summaries